Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10227568 | Biomaterials | 2014 | 9 Pages |
Abstract
Various tissue-specific antibodies have been attached to nanoparticles to obtain targeted delivery. In particular, nanodelivery systems with selectivity for breast, prostate and cancer tissue have been developed. Here, we have developed a nanodelivery system that targets the thyroid gland. Nanoliposomes have been conjugated to the thyroid-stimulating hormone (TSH), which binds to the TSH receptor (TSHr) on the surface of thyrocytes. The results indicate that the intracellular uptake of TSH-nanoliposomes is increased in cells expressing the TSHr. The accumulation of targeted nanoliposomes in the thyroid gland following intravenous injection was 3.5-fold higher in comparison to untargeted nanoliposomes. Furthermore, TSH-nanoliposomes encapsulated with gemcitabine showed improved anticancer efficacy in vitro and in a tumor model of follicular thyroid carcinoma. This drug delivery system could be used for the treatment of a broad spectrum of thyroid diseases to reduce side effects and improve therapeutic efficacy.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Donatella Paolino, Donato Cosco, Marco Gaspari, Marilena Celano, Joy Wolfram, Pasquale Voce, Efisio Puxeddu, Sebastiano Filetti, Christian Celia, Mauro Ferrari, Diego Russo, Massimo Fresta,